ArticleCureus2025
Effectiveness of Goreisan in Ménière's Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluates the effectiveness of Goreisan, a traditional Kampo medicine, in treating Ménière's disease (MD), focusing on vertigo frequency, dizziness severity, and hearing function.
methodsA retrospective analysis was conducted on 164 patients diagnosed with definite MD between April 2017 and March 2022. Among them, 52 patients received Goreisan treatment, while 31 patients did not receive any diuretic therapy. Vertigo frequency, Dizziness Handicap Inventory (DHI) scores, and hearing function were assessed over a 12-month period.
resultsPatients in the Goreisan group showed a significant reduction in vertigo frequency at two, six, and 12 months, whereas the no-medication group showed significant improvement only at two months. DHI scores improved in both groups, suggesting that betahistine and lifestyle modifications may contribute to symptom relief. No significant changes in hearing function were observed in the Goreisan group.
conclusionGoreisan may be an effective and safe treatment option for reducing vertigo frequency in MD patients. However, it does not appear to improve hearing function. Further placebo-controlled studies are needed to confirm its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.